- Our Company
- OXFAB® Technology
- OsteoFab® Products
- Contract Manufacturing
- News & Events
OPM Asia Announces Engagement of Curt Jennewine to Lead Commercial Development of Business throughout Asia
June 14th, 2018
SOUTH WINDSOR, Conn. and TOKYO, Japan (PRWEB) June 14, 2018- OPM Asia will establish a world-class biomedical manufacturing and market development operation in Japan for the Asian territory, and under the terms of the engagement, Mr. Jennewine will serve as OPM Asia’s Executive Vice President of Sales and Marketing. His objective is to identify partnering opportunities with Asian medical technology manufacturers that will generate near-term profitable growth as well as establish OPM’s 3D printed OsteoFab® implantable devices and OXPEKK® biomedical materials as technologies of choice in Japan and throughout Asia. Mr. Jennewine will begin by focusing on sales and marketing opportunities in Japan, China, Korea and Taiwan.
“We’re very excited to have Curt Jennewine lead our commercial efforts in Asia,” said Scott DeFelice, Chief Executive Officer of Oxford Performance Materials and OPM Asia. “Curt has demonstrated an impressive 20-year track record of commercial success for leading medical technology companies, with over 12 of those years in Asia. Curt has strong existing relationships with OPM Asia target customers, and his fluency in Japanese will facilitate the quick and effective growth of our Japanese business. We established OPM Asia to enable a broad introduction of OPM’s technology in Asia, and Curt has the perfect set of skills to accomplish that goal.”
Mr. Jennewine commented, “The increasing conversion to OPM’s PEKK-based products in the United States provides early Asian adopters with an outstanding opportunity to differentiate their portfolios and win share from their competitors. Research has shown that OPM’s 3D printed OsteoFab® implant surface technology provides strong osteoconductive as well as antibacterial characteristics. This technology offers significant, unique value to the patients, physicians and health care systems that adopt it.”
In the past Mr. Jennewine has held executive and leadership positions at companies such as Zimmer, Abbott, Acumed and Guidant. Mr. Jennewine earned his undergraduate degree at Duke University and his MBA at Northwestern’s Kellogg School of Management.
As previously announced in March, OPM was granted Accreditation of Foreign Medical Device Manufacturer status by the Japanese Ministry of Health, Labour and Welfare. OPM Asia is scheduled to establish its Japanese manufacturing facility in late 2018 with products commercially available to the Asian market in Q2, 2019.
About OPM Asia
OPM Asia is a partnership between Oxford Performance Materials, Inc. (OPM), a leader in advanced materials science and high performance additive manufacturing (HPAM®), and Tokyo-based JSR Corporation (JSR), a leading materials supplier in a variety of technology driven markets. A recognized leader in advanced materials science, OPM was founded in 2000 to exploit and commercialize the world’s highest performing thermoplastics, with a focus on poly-ether-ketone-ketone (PEKK). OPM develops proprietary material, process, and application technologies and applies high performance additive manufacturing (HPAM™) to produce fully functional, end-use structural parts. OPM Biomedical is a pioneer in personalized medicine, 3D printing OsteoFab® cranial and facial implants as an OEM, and spinal implants and additional products on a contract manufacturing basis. OPM Biomedical is the first and only company to receive FDA 510(k) clearance to manufacture 3D printed patient-specific polymeric implants and has a total of four 510(k) clearances in its portfolio. The OPM Materials business unit develops proprietary OXPEKK® thermoplastic products and other materials for biomedical, aerospace, defense, and industrial applications, including OXPEKK®-SC and OXPEKK®-LTS. For more information, please visit: http://www.oxfordpm.com
Oxford Performance Materials